Search Result

Results for "

p-ERK

" in MedChemExpress (MCE) Product Catalog:

By Targets:	ERK (8) Akt (1) Apoptosis (14) Autophagy (6) Cannabinoid Receptor (1) Caspase (1) CDK (1) DGK (2) Dopamine Receptor (1) EGFR (5) Eukaryotic Initiation Factor (eIF) (2) FGFR (1) FLT3 (2) Fungal (2) HDAC (1) HSP (1) Isotope-Labeled Compounds (2) JNK (1) MEK (7) mGluR (2) Microtubule/Tubulin (2) NF-κB (1) NO Synthase (1) p38 MAPK (1) PERK (20) Phosphatase (2) PI3K (2) PKC (1) PROTACs (3) Raf (1) RAR/RXR (1) Ras (16) SHP2 (4) Syk (2) Xanthine Oxidase (2)
By Research Areas:	Cancer (66) Cardiovascular Disease (2) Infection (3) Inflammation/Immunology (4) Metabolic Disease (4) Neurological Disease (7)

By Targets:

ERK (8)

Akt (1)

Apoptosis (14)

Autophagy (6)

Cannabinoid Receptor (1)

Caspase (1)

CDK (1)

DGK (2)

Dopamine Receptor (1)

EGFR (5)

Eukaryotic Initiation Factor (eIF) (2)

FGFR (1)

FLT3 (2)

Fungal (2)

HDAC (1)

HSP (1)

Isotope-Labeled Compounds (2)

JNK (1)

MEK (7)

mGluR (2)

Microtubule/Tubulin (2)

NF-κB (1)

NO Synthase (1)

p38 MAPK (1)

PERK (20)

Phosphatase (2)

PI3K (2)

PKC (1)

PROTACs (3)

Raf (1)

RAR/RXR (1)

Ras (16)

SHP2 (4)

Syk (2)

Xanthine Oxidase (2)

By Research Areas:

Cancer (66)

Cardiovascular Disease (2)

Infection (3)

Inflammation/Immunology (4)

Metabolic Disease (4)

Neurological Disease (7)

Inhibitors & Agonists

Screening Libraries

Natural
Products

Isotope-Labeled Compounds

Antibodies

Targets Recommended: ERK

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-135220

PERK-IN-2

PERK Cancer

PERK-IN-2 is a potent PERK inhibitor with an IC₅₀ of 0.2 nM .
HY-153160

PERK-IN-6

PERK Cancer

PERK-IN-6 (Compound 5) is a PERK inhibitor with an IC₅₀ of 2.5 nM .

PERK-IN-2	PERK	Cancer
PERK-IN-2 is a potent *PERK* inhibitor with an IC₅₀ of 0.2 nM .

PERK-IN-6	PERK	Cancer
PERK-IN-6 (Compound 5) is a *PERK* inhibitor with an IC₅₀ of 2.5 nM .

HY-145835

PERK-IN-5	PERK	Cancer
PERK-IN-5 is a highly potent, selectively and orally bioavailable *PERK* inhibitor (IC₅₀s of 2 and 9 nM for PERK and p-eIF2α, respectively). PERK-IN-5 can significantly inhibit tumor growth in the 786-O renal cell carcinoma xenograft tumor model .

HY-137813

PERK-IN-4	PERK	Neurological Disease Metabolic Disease Cancer
PERK-IN-4 is a potent and selective *PERK* (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC ₅₀ of 0.3 nM. *PERK* is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states .

HY-130643

PERK-IN-3

PERK Cancer

PERK-IN-3 is a potent PERK inhibitor with an IC₅₀ of 7.4 nM .

PERK-IN-3	PERK	Cancer
PERK-IN-3 is a potent *PERK* inhibitor with an IC₅₀ of 7.4 nM .

HY-137813S

PERK-IN-4-d3	Isotope-Labeled Compounds PERK	Neurological Disease Metabolic Disease Cancer
PERK-IN-4-d₃ is the deuterium labeled PERK-IN-4. PERK-IN-4 is a potent and selective PERK (protein kinase R (PKR)-like endoplasmic reticulum kinase) inhibitor with an IC 50 of 0.3 nM. PERK is activated in response to a variety of endoplasmic reticulum stresses implicated in numerous disease states[1].

HY-12661A

*AMG PERK* 44** 3 Publications Verification	PERK Autophagy	Cancer
AMG PERK 44 is an orally active and highly selective *PERK* inhibitor with an IC₅₀ of 6 nM. AMG PERK 44 has 1000-fold and 160-fold selectivity over GCN2 (IC₅₀=7300 nM) and B-Raf (IC₅₀ >1000 nM), respectively. AMG PERK 44 induces autophagy .

HY-145835A

(S)-PERK-IN-5

PERK Infection Cancer

(S)-PERK-IN-5 is the S-enantiomer of PERK-IN-5. (S)-PERK-IN-5 (example 39) is a PERK inhibitor, with an IC₅₀ of 0.101-0.250 μM .

*(S)-PERK-IN-5*	PERK	Infection Cancer
(S)-PERK-IN-5 is the S-enantiomer of PERK-IN-5. (S)-PERK-IN-5 (example 39) is a *PERK* inhibitor, with an IC₅₀ of 0.101-0.250 μM .

HY-142283AS

Dosimertinib mesylate	EGFR	Cancer
Dosimertinib-d₅ (mesylate) is a potent and orally active EGFR inhibitor. Dosimertinib-d₅ (mesylate) decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₅ (mesylate) shows antiproliferative and anti-tumor activity. Dosimertinib-d₅ (mesylate) has the potential for the research of non-small-cell lung cancer (NSCLC)[1].

HY-114453

SHP389

SHP2 Phosphatase Others

SHP389 is an allosteric SHP2 inhibitor, with an IC₅₀ of 36 nM for both SHP2 and p-ERK .

SHP389	SHP2 Phosphatase	Others
SHP389 is an allosteric SHP2 inhibitor, with an IC₅₀ of 36 nM for both SHP2 and p-ERK .

HY-146543

KRAS inhibitor-13	Ras	Cancer
KRAS inhibitor-13 (compound 5-6) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.883 µM. KRAS inhibitor-13 shows p-ERK inhibition activities with IC₅₀s of 5.9, >100 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-13 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-142283

Dosimertinib	Isotope-Labeled Compounds EGFR	Cancer
Dosimertinib-d₃-d₃ is a potent and orally active EGFR inhibitor. Dosimertinib-d₃-d₃ decreases the expression of p-EGFR and p-ERK protein levels. Dosimertinib-d₃-d₃ shows antiproliferative and anti-tumor activity. Dosimertinib-d₃-d₃ has the potential for the research of non-small-cell lung cancer (NSCLC)[1].

HY-146533

KRAS inhibitor-12	Ras	Cancer
KRAS inhibitor-12 (compound 6-1) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.537 µM. KRAS inhibitor-12 shows p-ERK inhibition activities with IC₅₀s of 1.3, 3.7 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-12 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146544

KRAS inhibitor-14	Ras	Cancer
KRAS inhibitor-14 (compound 3-22) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.249 µM. KRAS inhibitor-14 shows p-ERK inhibition activities with IC₅₀s of 1.12, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-14 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146545

KRAS inhibitor-15	Ras	Cancer
KRAS inhibitor-15 (compound 3-19) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.954 µM. KRAS inhibitor-15 shows p-ERK inhibition activities with IC₅₀s of 2.03, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-15 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146546

KRAS inhibitor-16	Ras	Cancer
KRAS inhibitor-16 (compound 3-11) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.457 µM. KRAS inhibitor-16 shows p-ERK inhibition activities with IC₅₀s of 3.06, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-16 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146475

KRAS inhibitor-17	Ras	Cancer
KRAS inhibitor-17 (compound 3-9) is a potent KRAS G12C inhibitor with an IC₅₀ of 3.37 µM. KRAS inhibitor-17 shows p-ERK inhibition activities with IC₅₀s of 9.25, >33.3 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-17 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146476

KRAS inhibitor-18	Ras	Cancer
KRAS inhibitor-18 (compound 3-10) is a potent KRAS G12C inhibitor with an IC₅₀ of 4.74 µM. KRAS inhibitor-18 shows p-ERK inhibition activities with IC₅₀s of 66.4, 11.1 µM in MIA PaCA-2, A549 cells, respectively. KRAS inhibitor-18 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-146537

KRAS G12C inhibitor 47	Ras	Cancer
KRAS G12C inhibitor 47 (compound 8-1-1) is a potent KRAS G12C inhibitor with an IC₅₀ of 0.172 µM. KRAS G12C inhibitor 47 shows p-ERK inhibition activities with IC₅₀s of 0.046, 69.8 µM in MIA PaCA-2, A549 cells, respectively. KRAS G12C inhibitor 47 has the potential for the research of pancreatic, colorectal, and lung cancers .

HY-153832

MSU-42011	RAR/RXR NO Synthase	Cancer
MSU-42011 is an orally active retinoid X receptor (RXR) agonist. MSU-42011 inhibits the iNOS activity and reduces the expression of *p-ERK* protein. MSU-42011 has immunomodulatory and antitumor activity .

HY-107471

CB2 receptor agonist 3 GP2a	Cannabinoid Receptor	Cancer
CB2 receptor agonist 3 is a robust and selective CB2 cannabinoid agonist with K_is of 7.6 and 900 nM for CB2 and CB1, respectively. CB2 receptor agonist 3 significantly increases P-ERK 1/2 expression in HL-60 cells .

HY-N2450

Sulforaphene	Apoptosis EGFR ERK NF-κB Microtubule/Tubulin	Cancer
Sulforaphene, isolated from radish seeds, exhibits an ED₅₀ against velvetleaf seedlings approximately 2 x 10 ^-4 M. Sulforaphene promotes cancer cells apoptosis and inhibits migration via inhibiting EGFR, *p-ERK1/2, NF‐κB* and other signals .

HY-N0745

Senkyunolide I	Caspase	Inflammation/Immunology
Senkyunolide I, isolated from Ligusticum chuanxiong Hort, is an anti-migraine compound. Senkyunolide I protects rat brain against focal cerebral ischemia-reperfusion injury by up-regulating p-Erk1/2, Nrf2/HO-1 and inhibiting caspase 3 .

HY-10254

Mirdametinib Maximum Cited Publications 82 Publications Verification PD0325901; PD325901	MEK Autophagy Apoptosis	Cancer
Mirdametinib (PD0325901) is an orally active, selective and non-ATP-competitive MEK inhibitor with an IC₅₀ of 0.33 nM. Mirdametinib exhibits a K_i ^app of 1 nM against activated MEK1 and MEK2. Mirdametinib suppresses the expression of p-ERK1/2 and induces apoptosis. Mirdametinib has anti-cancer activity for a broad spectrum of human tumor xenografts .

HY-147513

AKT-IN-12	Akt Apoptosis	Cancer
AKT-IN-12 (compound 3e) is a potent Akt kinase inhibitor with an IC₅₀ value of 0.55 μM. AKT-IN-12 induces G0/G1 cell cycle arrest and apoptosis. AKT-IN-12 also inhibits p-AKT, p-ERK, and activates p-JNK, JNK. AKT-IN-12 can be used for researching leukemia .

HY-100403

Ro 67-7476 5+ Cited Publications	mGluR	Cancer
Ro 67-7476 is a potent positive allosteric modulator of mGluR₁ and potentiates glutamate-induced calcium release in HEK293 cells expressing rat mGluR1a with an EC₅₀ of 60.1 nM . Ro 67-7476 is a potent P-ERK1/2 agonist and activates ERK1/2 phosphorylation in the absence of exogenously added glutamate (EC₅₀=163.3 nM) .

HY-119240

CCT020312

15+ Cited Publications

PERK Autophagy Neurological Disease Cancer

CCT020312 is a selective EIF2AK3/PERK activator. CCT020312 elicits EIF2A phosphorylation in cells.

CCT020312 15+ Cited Publications	PERK Autophagy	Neurological Disease Cancer
CCT020312 is a selective *EIF2AK3/PERK* activator. CCT020312 elicits EIF2A phosphorylation in cells.

HY-145015

Tuspetinib HM43239	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-117720

OSU-2S	PKC Apoptosis	Cancer
OSU-2S is a potent PKCδ activator. OSU-2S inhibits cell proliferation and migration. OSU-2S decreases the expression of p-ERK1/2, increases the expression of PKCδ (38 kDa) when combined with Sorafenib (HY-10201). OSU-2S induces Apoptosis. OSU-2S slao is a non-immunosuppressive analogue of FTY720. OSU-2S shows anticancer activity .

HY-113916

Onalespib lactate AT13387 lactate	HSP	Cancer
Onalespib lactate is a potent and cross the blood-brain barrier heat-shock-protein-90 (Hsp90) inhibitor with an K_d value of 0.71 nM. Onalespib lactate inhibits the proliferation, survival and migration. Onalespib lactate decreases the expression of EGFR, p-EGFR, AKT, P-AKT, ERK1/2, P-ERK1/2, S6, P-S6 protein. Onalespib lactate shows antitumor activity. Onalespib lactate has the potential for the research of non-small cell lung cancer (NSCLC) .

HY-145015A

Tuspetinib hydrate HM43239 hydrate	FLT3 Apoptosis	Cancer
Tuspetinib (HM43239) hydrate is an orally active and selective FLT3 inhibitor with IC₅₀s of 1.1 nM, 1.8 nM and 1.0 nM for FLT3 WT, FLT3 internal tandem duplication (ITD) and FLT3 D835Y kinases, respectively. Tuspetinib hydrate inhibits the kinase activity of FLT3 as a reversible type I inhibitor and modulates p-STAT5, p-ERK, SYK, JAK1/2, and TAK1. Tuspetinib hydrate inhibits the proliferation and induces the apoptosis of leukemic cells .

HY-107415

PLX7922

Raf Cancer

PLX7922, a RAF inhibitor, can bind with BRAF ^V600E. PLX7922 inhibits pERK in BRAF ^V600E cell lines, and activates pERK in mutant NRAS cell lines .

PLX7922	Raf	Cancer
PLX7922, a RAF inhibitor, can bind with BRAF ^V600E. PLX7922 inhibits pERK in BRAF ^V600E cell lines, and activates pERK in mutant NRAS cell lines .

HY-114978

VU0424465	mGluR PERK	Neurological Disease
VU0424465 is a potent and partial PAM (positive allosteric modulator)-agonist for mGlu₅ mediated iCa ²⁺ mobilization. VU0424465 exhibits high affinity at MPEP allosteric binding site, with a K_i value of 11.8 nM. VU0424465 is also a agonist for pERK1/2 in cortical neurons .

HY-N3480

Isogosferol (+)-Isogospherol; Isogospherol	Others	Inflammation/Immunology
Isogosferol ((+)-Isogospherol; Isogospherol) is a potent anti-inflammatory agent. Isogosferol decreases LPS (HY-D1056)-stimulated NO and IL-1β expression. Isogosferol decreases the LPS (HY-D1056)-stimulated expression of iNOS, COX-2, NF-κB, and pERK1/2 .

HY-155098

CNBCA	SHP2	Cancer
CNBCA is a potent, selective, competitive SHP2 enzyme inhibitor, with the IC₅₀ of 0.87 μM. CNBCA binds to full-length SHP2 and inhibits enzyme activity. CNBCA inhibits pAkt and pERK1/2, and the cell growth of BT474 and MDA-MB468 cells. CNBCA can be used for breast cancer study .

HY-13820

GSK2656157 35+ Cited Publications	PERK Autophagy Apoptosis	Cancer
GSK2656157 is a selective and ATP-competitive inhibitor of protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) with an IC₅₀ of 0.9 nM.

HY-114189

GW284543

UNC10225170
MEK Cancer

GW284543 (UNC10225170) is a selective MEK5 inhibitor. GW284543 reduces pERK5, and decreases endogenous MYC protein .

GW284543 UNC10225170	MEK	Cancer
GW284543 (UNC10225170) is a selective MEK5 inhibitor. GW284543 reduces pERK5, and decreases endogenous MYC protein .

HY-114189A

GW284543 hydrochloride UNC10225170 hydrochloride	MEK	Cancer
GW284543 (UNC10225170) hydrochloride is a selective MEK5 inhibitor. GW284543 reduces pERK5, and decreases endogenous MYC protein .

HY-149824

EGFR T790M/L858R-IN-2	EGFR Apoptosis	Cancer
EGFRT790M/L858R-IN-2 is a potent and selective EGFRT790M/L858R inhibitor with IC₅₀ values of 3.5, 1290 nM for EGFRT790M/L858R, EGFR WT, respectively. EGFRT790M/L858R-IN-2 decreases the expression of p-EGFR, P-AKT, P-ERK1/2. EGFRT790M/L858R-IN-2 induces Apoptosis and cell cycle arrest in the G1 phase. EGFRT790M/L858R-IN-2 shows anti-cancer activity .

HY-18072

GSK2606414 65+ Cited Publications	PERK Autophagy Apoptosis	Cancer
GSK2606414 is a cell-permeable and orally available protein kinase R-like endoplasmic reticulum (ER) kinase (PERK) inhibitor with an IC₅₀ of 0.4 nM.

HY-137207

MK-28 3 Publications Verification	PERK	Neurological Disease
MK-28 is a potent and selective *PERK* activator. MK-28 exhibits remarkable pharmacokinetic properties and high BBB penetration in mice .

HY-12495

ISRIB (trans-isomer) 20+ Cited Publications	PERK Autophagy Apoptosis	Neurological Disease
ISRIB (trans-isomer) is a potent inhibitor of *PERK* with an IC₅₀ of 5 nM. ISRIB potently reverses the effects of eIF2α phosphorylation (IC₅₀=5 nM).

HY-153343

BAY 2965501	DGK	Cancer
BAY 2965501 is a potent and selective diacylglycerol kinase zeta (DGKζ) inhibitor. BAY 2965501 induces pERK activation. BAY 2965501 can be used for the research of cancer .

HY-153740

PF-07284892

ARRY-558
SHP2 Cancer

PF-07284892 (ARRY-558) is a potent and orally active SHP2 inhibitor with an IC₅₀ value of 21 nM. PF-07284892 decreases the expression of pERK .

PF-07284892 ARRY-558	SHP2	Cancer
PF-07284892 (ARRY-558) is a potent and orally active SHP2 inhibitor with an IC₅₀ value of 21 nM. PF-07284892 decreases the expression of pERK .

HY-157231

HC-5404	PERK	Cancer
HC-5404 is a potent and selective *PERK* inhibitor. HC-5404 has orally activity. HC-5404 significantly blocks metastasis via killing quiescent/slow-cycling ISRhigh .

HY-161235

BTX-7312	Ras	Cancer
BTX-7312 is a SOS1 cereblon-based bifunctional degrader. BTX-7312 reduces downstream signaling markers, pERK and pS6, and displays antiproliferative activity in cells harboring various KRAS mutations .

HY-161236

KRAS ligand 4	Ras	Cancer
KRAS ligand 4 (Compound 2) is a bifunctional depressant based on SOS1. KRAS ligand 4 reduces the downstream signaling markers pERK and pS6 and shows anti-proliferative activity in multiple KRAS mutated cells .

HY-144692

MEK/PI3K-IN-1	MEK PI3K PERK	Cancer
MEK/PI3K-IN-1 (compound 6r) is a potent MEK/PI3K inhibitor, with IC₅₀ values of 124 nM (MEK1), 130 nM (PI3Kα), and 236 nM (PI3Kδ), respectively. MEK/PI3K-IN-1 suppresses pAKT and pERK1/2 levels. MEK/PI3K-IN-1 shows anti-proliferative activity against tumor cell lines .

HY-144693

MEK/PI3K-IN-2	MEK PI3K PERK	Cancer
MEK/PI3K-IN-2 (compound 6s) is a potent MEK/PI3K inhibitor, with IC₅₀ values of 352 nM (MEK1), 107 nM (PI3Kα), and 137 nM (PI3Kδ), respectively. MEK/PI3K-IN-2 suppresses pAKT and pERK1/2 levels. MEK/PI3K-IN-2 shows anti-proliferative activity against tumor cell lines .

HY-144965

SOS1-IN-12	Ras	Cancer
SOS1-IN-12 is a potent son of sevenless homolog 1 (SOS1) inhibitor with a K_i of 0.11 nM for SOS1 and an IC₅₀ of 47 nM for pERK. SOS1-IN-13 can be used for researching anticancer .

Cat. No.	Product Name	Category	Target	Chemical Structure